{"id":"W2007084442","doi":"10.2147/dddt.s14071","title":"A Phase I study of an intravesically administered immunotoxin targeting EpCAM for the treatment of nonmuscle-invasive bladder cancer in BCG-refractory and BCG-intolerant patients","year":2010,"lang":"en","type":"article","venue":"Drug Design Development and Therapy","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":72,"is_retracted":false,"has_abstract":true,"ca_institutions":"Viventia Bio (Canada)","funders":"","keywords":"Medicine; Tolerability; Refractory (planetary science); Adverse effect; Bladder cancer; Urology; Toxicity; Pharmacokinetics; Internal medicine; Maximum tolerated dose; Clinical endpoint; Gastroenterology; Surgery; Clinical trial; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008278279,0.0008819707,0.001153999,0.000277559,0.0002734006,0.0004951353,0.000690976,0.0008702231,0.001479176],"category_scores_gemma":[0.0004037715,0.0003642341,0.000696943,0.0002287591,0.0005956545,0.0003652467,0.0002432048,0.001754623,0.0003395482],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005171504,"about_ca_system_score_gemma":0.000880608,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000422756,"about_ca_topic_score_gemma":0.0009065031,"domain_scores_codex":[0.9997546,0.0001024274,0.00001389926,0.00004148736,0.00002444523,0.00006308012],"domain_scores_gemma":[0.9995933,0.0000566378,0.0001010797,0.00003711798,0.00002448263,0.000187477],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.3425482,0.1194818,0.01886195,0.001280985,0.001211312,0.0007149052,0.000638657,0.004699083,0.3441039,0.0004026166,0.001936421,0.1641201],"study_design_scores_gemma":[0.2030777,0.7559076,0.02105611,0.00003529758,0.000324737,0.0005475279,0.00005323598,0.001396518,0.01574122,0.000100245,0.001736164,0.00002370861],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9979032,0.0005657701,0.0003493338,0.00007848183,0.00002419414,0.0006715747,0.0001030899,0.00002296537,0.0002814842],"genre_scores_gemma":[0.9956802,0.0005341629,0.001325348,0.0002940075,0.00005580972,0.0008889053,0.000506559,0.000008940446,0.0007059567],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001479176,"threshold_uncertainty_score":0.004948318,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03116886744117042,"score_gpt":0.3167600006688397,"score_spread":0.2855911332276693,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}